作者
Clare A Aitken, Heleen ME van Agt, Albert G Siebers, Folkert J van Kemenade, Hubert GM Niesters, Willem JG Melchers, Judith EM Vedder, Rob Schuurman, Adriaan JC van den Brule, Hans C van der Linden, John WJ Hinrichs, Anco Molijn, Klaas J Hoogduin, Bettien M van Hemel, Inge MCM de Kok
发表日期
2019/12
期刊
BMC medicine
卷号
17
页码范围
1-14
出版商
BioMed Central
简介
Abstract
Background
In January 2017, the Dutch cervical cancer screening programme transitioned from cytomorphological to primary high-risk HPV (hrHPV) DNA screening, including the introduction of self-sampling, for women aged between 30 and 60 years. The Netherlands was the first country to switch to hrHPV screening at the national level. We investigated the health impact of this transition by comparing performance indicators from the new hrHPV-based programme with the previous cytology-based programme.
Methods
We obtained data from the Dutch nationwide network and registry of histo- and cytopathology (PALGA) for 454,573 women eligible for screening in 2017 who participated in the hrHPV-based programme between 1 January 2017 and 30 June 2018 (maximum follow-up of almost 21 months) and for 483,146 women eligible for screening in 2015 who participated in the cytology-based …
学术搜索中的文章
CA Aitken, HME van Agt, AG Siebers… - BMC medicine, 2019